Supernus Pharmaceuticals (NASDAQ:SUPN) Raised to “Buy” at BidaskClub

BidaskClub upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a hold rating to a buy rating in a report issued on Thursday morning, BidAskClub reports.

Other equities research analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, August 16th. Cowen set a $50.00 target price on shares of Supernus Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, August 7th. Mizuho restated a buy rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, August 7th. Stifel Nicolaus set a $55.00 target price on shares of Supernus Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, August 7th. Finally, Jefferies Financial Group set a $46.00 target price on shares of Supernus Pharmaceuticals and gave the company a buy rating in a research note on Friday, August 30th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $53.38.

SUPN opened at $27.53 on Thursday. Supernus Pharmaceuticals has a fifty-two week low of $25.32 and a fifty-two week high of $51.38. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.72 and a quick ratio of 2.53. The firm’s fifty day moving average price is $28.76 and its two-hundred day moving average price is $33.24. The company has a market capitalization of $1.46 billion, a P/E ratio of 13.43, a P/E/G ratio of 0.98 and a beta of 1.62.



Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.61 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.05. Supernus Pharmaceuticals had a net margin of 25.66% and a return on equity of 22.36%. The company had revenue of $104.70 million for the quarter, compared to the consensus estimate of $109.67 million. During the same quarter in the previous year, the company earned $0.57 EPS. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, equities research analysts expect that Supernus Pharmaceuticals will post 2.16 EPS for the current fiscal year.

In related news, CEO Jack A. Khattar purchased 7,200 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, August 23rd. The shares were acquired at an average price of $26.39 per share, for a total transaction of $190,008.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 6.57% of the stock is owned by corporate insiders.

Institutional investors have recently modified their holdings of the stock. Municipal Employees Retirement System of Michigan raised its position in Supernus Pharmaceuticals by 2.2% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 15,650 shares of the specialty pharmaceutical company’s stock worth $518,000 after purchasing an additional 330 shares during the last quarter. Bridge City Capital LLC raised its position in Supernus Pharmaceuticals by 0.5% in the 2nd quarter. Bridge City Capital LLC now owns 69,000 shares of the specialty pharmaceutical company’s stock worth $2,283,000 after purchasing an additional 338 shares during the last quarter. Oregon Public Employees Retirement Fund raised its position in Supernus Pharmaceuticals by 1.8% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 20,239 shares of the specialty pharmaceutical company’s stock worth $709,000 after purchasing an additional 366 shares during the last quarter. Baltimore Washington Financial Advisors Inc. raised its position in Supernus Pharmaceuticals by 0.9% in the 2nd quarter. Baltimore Washington Financial Advisors Inc. now owns 45,033 shares of the specialty pharmaceutical company’s stock worth $1,490,000 after purchasing an additional 420 shares during the last quarter. Finally, Diversified Trust Co raised its position in Supernus Pharmaceuticals by 8.4% in the 2nd quarter. Diversified Trust Co now owns 6,450 shares of the specialty pharmaceutical company’s stock worth $213,000 after purchasing an additional 500 shares during the last quarter. 99.35% of the stock is owned by institutional investors and hedge funds.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Recommended Story: Systematic Risk

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.